K.1.1. Erythropoietin versus placebo

Figure 1. All-cause mortality at 30 days

Figure 2. Number of patients transfused

Figure 1. Number of patients transfused – sub-grouped by presence/absence of anaemia at baseline

Figure 4. Number of units transfused per patient

Figure 2. Number of units transfused per patient – sub-grouped by presence/absence of anaemia at baseline

Figure 3. Serious adverse events

Figure 4. Thrombosis

Figure 5. Length of hospital stay

Figure 6. Infection (pneumonia)

K.1.2. IV iron versus placebo or no IV iron

Figure 7. All-cause mortality at 30 days

Figure 8. Number of patients transfused

Figure 9. Length of hospital stay

Figure 10. Serious adverse events

Figure 11. Infections

K.1.3. Oral iron versus placebo or no oral iron

Figure 12. Number of patients transfused

K.1.4. Erythropoietin plus IV iron versus placebo

Figure 13. All-cause mortality at 30 days

Figure 14. Number of patients transfused

Figure 15. Number of units transfused per patient

Figure 16. Number of units transfused per patient- sub-grouped by presence/absence of anaemia at baseline

Figure 17. Length of hospital stay

Figure 18. Serious adverse events

K.1.5. Oral iron versus IV iron

Figure 19. Number of patients transfused

Figure 20. Length of hospital stay

Figure 21. Deep vein thrombosis (DVT)

Figure 22. Quality of life (Total EQ-5D scores)

K.1.6. Erythropoietin plus IV iron versus IV iron

Figure 23. All-cause mortality at 30 days

Figure 24. Number of patients transfused

Figure 25. Serious adverse events

K.1.7. Erythropoietin plus oral iron versus oral iron

Figure 26. All-cause mortality at 30 days

Figure 27. Number of patients transfused

Figure 28. Length of hospital stay

Figure 29. Infections

Figure 30. Deep vein thrombosis (DVT)

Figure 31. Other thrombovascular events

K.1.8. Erythropoietin plus oral iron or IV iron versus oral iron or IV iron

Figure 32. Mortality (all-cause)

Figure 33. Serious adverse events

Figure 34. Thrombosis

K.2.1. Adults - high risk

Figure 35. ICS versus standard treatment- Number exposed to allogeneic blood

Figure 36. ICS versus standard treatment- Units of allogeneic blood transfused

Figure 37. ICS versus standard treatment- Mortality at up to 30 days

Figure 38. ICS versus standard treatment- Infection

Figure 39. ICS versus standard treatment- Length of stay in hospital

Figure 40. PCS versus standard treatment- Number exposed to allogeneic blood

Figure 41. PCS versus standard treatment- Units of allogeneic blood transfused

Figure 42. PCS versus standard treatment- Mortality at up to 30 days

Figure 43. PCS versus standard treatment- Infection

Figure 44. PCS versus standard treatment- Length of stay in hospital

Figure 45. ICS plus PCS versus standard treatment- Number exposed to allogeneic blood

Figure 46. ICS plus PCS versus standard treatment- Mortality at up to 30 days

Figure 47. ICS plus PCS versus standard treatment- Infection

Figure 48. ICS plus PCS versus standard treatment- Length of stay in hospital

Figure 49. ICS plus TXA versus ICS- Number exposed to allogeneic blood

Figure 50. ICS plus TXA versus ICS - Units of allogeneic blood transfused

Figure 51. ICS plus TXA versus ICS- Mortality at up to 30 days

Figure 52. ICS plus TXA versus ICS- Length of stay in hospital

Figure 53. ICS plus TXA versus TXA- Number exposed to allogeneic blood

Figure 54. ICS plus TXA versus TXA- Mortality at up to 30 days

Figure 55. ICS plus TXA versus TXA- Infections

Figure 56. ICS+TXA versus TXA- Length of stay in hospital

Figure 57. PCS plus TXA versus TXA- No. exposed to allogeneic blood

Figure 58. ICS plus PCS plus TXA versus ICS plus PCS- Number exposed to allogeneic blood

Figure 59. ICS plus PCS plus TXA versus ICS plus PCS- Units of allogeneic blood transfused

Figure 60. ICS plus PCS plus TXA versus ICS plus PCS- Mortality at up to 30 days

Figure 61. ICS plus PCS plus TXA versus TXA- Number exposed to allogeneic blood

Figure 62. ICS plus PCS plus TXA versus TXA- Infection

Figure 63. TXA versus standard treatment- Number exposed to allogeneic transfusions

Figure 64. TXA versus standard treatment- Units of allogeneic blood transfused

Figure 65. TXA versus standard treatment- Mortality

Figure 66. TXA versus standard treatment- Length of hospital stay

Figure 67. TXA versus standard treatment- Thrombotic complications

Figure 68. Infections

K.2.2. Adults - moderate risk

Figure 69. ICS versus standard treatment- Number exposed to allogeneic blood

Figure 70. ICS versus standard treatment- Units of allogeneic blood transfused

Figure 71. PCS versus standard treatment- Number exposed to allogeneic blood

Figure 72. PCS versus standard treatment- Units of allogeneic blood transfused

Figure 73. PCS versus standard treatment- Infection

Figure 74. PCS versus standard treatment- Length of hospital stay

Figure 75. ICS plus PCS versus standard treatment- Number exposed to allogeneic blood

Figure 76. ICS plus PCS versus standard treatment- Units of allogeneic blood transfused

Figure 77. ICS plus PCS versus standard treatment- Mortality

Figure 78. ICS plus PCS versus standard treatment- Infection

Figure 79. ICS plus PCS versus standard treatment- Length of hospital stay

Figure 80. ICS plus PCS versus PCS- No.of patients receiving allogeneic transfusions

Figure 81. ICS plus PCS versus PCS- Units of allogeneic blood transfused

Figure 82. ICS plus TXA versus ICS- Number exposed to allogeneic blood

Figure 83. ICS plus TXA versus ICS- Units of allogeneic blood transfused

Figure 84. ICS plus TXA versus ICS- Length of hospital stay

Figure 85. PCS plus TXA versus PCS- Number exposed to allogeneic blood

Figure 86. PCS plus TXA versus PCS- Thrombotic complications

Figure 87. ICS plus PCS plus TXA versus TXA- No. exposed to allogeneic blood

Figure 88. ICS plus PCS plus TXA versus TXA- Units of allogeneic blood transfused

Figure 89. TXA versus standard treatment- Number exposed to allogeneic transfusions

Figure 90. TXA versus standard treatment- Units of allogeneic blood transfused

Figure 91. TXA versus standard treatment- Mortality

Figure 92. TXA versus standard treatment- Length of hospital stay

Figure 93. TXA versus standard treatment- Infections

Figure 94. TXA versus standard treatment- Thrombotic complications

K.2.3. Adult- Low risk group

Figure 95. TXA versus standard treatment- Number exposed to allogeneic blood

Figure 96. TXA versus standard treatment- Blood loss

Figure 97. Thrombotic complications

K.2.4. Children - high risk

Figure 98. ICS plus TXA versus ICS- Number exposed to allogeneic blood

Figure 99. ICS plus TXA versus ICS- Total blood transfused

Figure 100. ICS plus TXA versus ICS- Total blood loss

Figure 101. TXA versus standard treatment- Post-operative blood loss

Figure 102. Length of hospital stay

K.3.1. RBC thresholds - adults

Figure 103. Number of patients needing transfusion

Figure 104. Number of units of blood transfused in those transfused (adults)

Figure 105. Length of stay in hospital (adults)

Figure 106. All-cause mortality (30 days)

Figure 107. New cardiac events (MI,CHF)

Figure 108. Infections

Figure 109. Adverse events (adults)

Figure 110. Adverse events (adults)-TACO

Figure 111. Adverse events (adults)-TRALI

K.3.2. RBC thresholds - children

Figure 112. Total RBC ml/patient (children)

Figure 113. Number of units transfused-children

Figure 114. Number of patients needing transfusion -children

Figure 115. Number of patients needing transfusion -children (sub-group analysis)

Figure 116. Mortality at 30 days (all-cause)- children

Figure 117. ICU length of stay (children)

Figure 118. Pulmonary oedema (children)

Figure 119. Infections (nosocomial infections) -children

K.3.3. Target haemoglobin concentrations for blood transfusion

Figure 120. Number of patients needing transfusions-adults

K.5.1. Low dose versus medium dose

Figure 134. Number of patients with bleeding (WHO grade 2 and above)

Figure 135. All-cause mortality at 30 days

Figure 136. Infections

Figure 137. Serious adverse event (any)

K.5.2. High dose versus medium dose

Figure 138. Number of patients with bleeding (WHO grade 2 and above)

Figure 139. All-cause mortality at 30 days

Figure 140. Infections

Figure 141. Serious adverse events (any)

K.5.3. Low dose versus high dose

Figure 142. Number of patients with bleeding (WHO grade 2 and above)

Figure 143. All-cause mortality at 30 days

Figure 144. Infections

Figure 145. Serious adverse events (any)

K.5.4. Platelet thresholds and Targets

Prophylactic transfusion versus no prophylactic transfusion - adults who are haematology patients (non-bleeding patients)

Figure 146. Number of patients with bleeding events (WHO grade 2 or higher)

Figure 147. Number of patients with major bleeding events (WHO grade 3 or 4)

Figure 148. Serious adverse events (including sepsis and respiratory deterioration)

Figure 149. Transfusion related serious adverse event (urticarial and angioedema)

Figure 150. Number of patients needing platelet transfusion

Figure 151. Number of units (platelets) transfused per patient

Figure 152. Mortality (all cause)

Figure 153. Side effects of transfusion (not specified)

K.5.5. Prophylactic transfusion versus no prophylactic transfusion - children who are haematology patients (non-bleeding patients)

Figure 154. Number of patients with major bleeding events (WHO grade 3 or 4)

Figure 155. Mortality (all cause) 3 years

Figure 156. Mortality from bleeding (3 years)

K.5.6. Low threshold versus high threshold - adults who are haematology patients (non-bleeding patients)

Figure 157. Mortality (all cause)

Figure 158. Number of patients with bleeding events (WHO grade 2 or higher)

Figure 159. Number of patients with major bleeding events (WHO grade 3 or 4)

Figure 160. Infections

Figure 161. Adverse events

Figure 162. Number of units (platelets) transfused per patient

K.6.1. Therapeutic FFP transfusion versus no FFP transfusion

Figure 163. Mortality (all-cause)

Figure 164. Adverse events

K.7.1. Low dose (25 IU/kg) versus high dose (40 IU/kg)

Figure 165. Mortality

Figure 166. Patients with at least one adverse event

Figure 167. Patients with at least one serious adverse event

Figure 168. Patients with at least one thrombotic event

Figure 169. Target INR less than 1.2 achieved

K.7.2. Low fixed dose (1040 IU FIX) versus variable dose

Figure 170. Target INR reached

Figure 171. Deep Vein Thrombosis (DVT)

Figure 172. Mortality

K.7.3. Standard dose (500 IU FIX/7 IU FIX/kg) versus individualised dosing regimen

Figure 173. Target INR at 15 minutes after the first dosage of PCC

Figure 174. Serious adverse events

K.8.1. Cryoprecipitate versus no cryoprecipitate

Figure 175. Mortality at 30 days (all-cause)